{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:04:53Z","timestamp":1789535093706,"version":"build-2803163510"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Purposes<\/jats:title>\n                    <jats:p>Individual molecular features are insufficient to elucidate the complex biological properties of pan-cancer. Accordingly, this study performed pan-cancer molecular subtyping based on pathway activation signatures to dissect the heterogeneity and commonality across malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Transcriptomic data for 7,138 pan-cancer samples were retrieved from TCGA database for molecular subtyping. In parallel, transcriptomic data for 597 cell lines and drug sensitivity data for 269 lines were obtained from CCLE database for drug sensitivity analysis, and transcriptomic profiles of 16 in-house cell lines were incorporated for combined analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Using unsupervised clustering, we classified pan-cancer into four distinct molecular subtypes based on the activity of 43 key cancer-related pathways. C1 was enriched for upregulated pathways involved in oncogenic signaling, cellular processes-related and immune pathways. C2 was characterized by upregulated activation of metabolic and DNA damage response (DDR) pathways. C3 displayed upregulated activity of metabolic, DDR and immune pathways. C4 showed elevated activity of oncogenic signaling, cellular processes-related, and DDR pathways. Notably, compared with C2 and C4, C1 and C3 displayed enhanced immune score, increased CD8+T cell infiltration and higher expression of genes involving in antigen processing and presentation, immunogenic cell death and immune checkpoint. C3 demonstrated the most favorable overall survival and the lowest proportion of progressive\/stable disease patients, followed by C1, whereas C2 and C4 were associated with inferior clinical outcomes. C3 was susceptible to multiple agents, while C1 showed multidrug resistance. Moreover,\n                      <jats:italic>in vitro<\/jats:italic>\n                      cellular experiments demonstrated that combined treatment with inhibitors targeting activated pathways yielded superior inhibitory effects relative to monotherapy for C1, C2 and C4.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overall, our study defined four molecular subtypes based on the pathway activation profiles, with each subtype displaying unique features in pathway activation, clinical manifestations, treatment response, survival prognosis, immune microenvironment, and drug sensitivity. These findings may provide potential valuable insights for the precise diagnosis and treatment of cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1918117","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:34:52Z","timestamp":1789533292000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Delineation of molecular subtypes based on pathway activation signatures reveals intrinsic tumor heterogeneity and pan-cancer shared features"],"prefix":"10.3389","volume":"16","author":[{"given":"Ren","family":"Xu","sequence":"first","affiliation":[{"name":"School of Physics, Changchun University of Science and Technology","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Xiao","sequence":"additional","affiliation":[{"name":"School of Physics, Changchun University of Science and Technology","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinglin","family":"Yang","sequence":"additional","affiliation":[{"name":"School of Physics, Changchun University of Science and Technology","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Life Science and Technology, Changchun University of Science and Technology","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanhua","family":"Yu","sequence":"additional","affiliation":[{"name":"School of Physics, Changchun University of Science and Technology","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Life Science and Technology, Changchun University of Science and Technology","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41698-022-00269-5","article-title":"Pan-cancer prognostic genetic mutations and clinicopathological factors associated with survival outcomes: a systematic review","volume":"6","author":"Gammall","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s41586-023-06130-4","article-title":"Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours","volume":"618","author":"Gavish","year":"2023","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0355-0","article-title":"A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling","volume":"30","author":"Qian","year":"2020","journal-title":"Cell Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00250-4","article-title":"Moving pan-cancer studies from basic research toward the clinic","volume":"2","author":"Chen","year":"2021","journal-title":"Nat Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1038\/s41467-023-39136-7","article-title":"Pan-cancer and cross-population genome-wide association studies dissect shared genetic backgrounds underlying carcinogenesis","volume":"14","author":"Sato","year":"2023","journal-title":"Nat Commun"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2021.104606","article-title":"Application of high-throughput gene sequencing in lymphoma","volume":"119","author":"Lv","year":"2021","journal-title":"Exp Mol Pathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nature25795","article-title":"Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours","volume":"555","author":"Ma","year":"2018","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5415758","article-title":"Delineating molecular subtypes through gene set variation analysis confers therapeutic and prognostic capability in gastric cancer","volume":"2022","author":"Zhu","year":"2022","journal-title":"Can J Gastroenterol Hepatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01197-w","article-title":"Immune landscape-driven subtyping reveals distinct microenvironment and prognostic profiles in thymic epithelial tumors","volume":"10","author":"Zhang","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2025.100752","article-title":"Pan-cancer molecular biomarkers: Practical considerations for the surgical pathologist","volume":"38","author":"Jafari","year":"2025","journal-title":"Mod Pathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-23-0725","article-title":"Emerging tumor-agnostic molecular targets","volume":"23","author":"Bhamidipati","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102340","article-title":"Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours","volume":"104","author":"Crucitta","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B14","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41571-025-01109-8","article-title":"Discovery of predictive biomarkers for cancer therapy through computational approaches","volume":"23","author":"Wang","year":"2026","journal-title":"Nat Rev Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa050736","article-title":"Erlotinib in lung cancer - molecular and clinical predictors of outcome","volume":"353","author":"Tsao","year":"2005","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.3390\/biomedicines9111502","article-title":"Pathway-based personalized analysis of pan-cancer transcriptomic data","volume":"9","author":"Pian","year":"2021","journal-title":"Biomedicines"},{"key":"B17","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12859-020-3423-z","article-title":"Comparison of pathway and gene-level models for cancer prognosis prediction","volume":"21","author":"Zheng","year":"2020","journal-title":"BMC Bioinf"},{"key":"B18","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in The Cancer Genome Atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-023-00612-3","article-title":"Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters","volume":"23","author":"Sajid","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3892\/ijmm.2022.5184","article-title":"CDK4\/6 inhibitor resistance mechanisms and treatment strategies (Review)","volume":"50","author":"Huang","year":"2022","journal-title":"Int J Mol Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1212986","article-title":"Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib","volume":"14","author":"Zhu","year":"2023","journal-title":"Front Pharmacol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.4324\/9780429434815-5","article-title":"Targeting activated PI3K\/mTOR signaling overcomes acquired resistance to CDK4\/6-based therapies in preclinical models of hormone receptor-positive breast cancer","volume":"22","author":"O'Brien","year":"2020","journal-title":"Breast Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/s41467-019-09068-2","article-title":"Aberrant FGFR signaling mediates resistance to CDK4\/6 inhibitors in ER+ breast cancer","volume":"10","author":"Formisano","year":"2019","journal-title":"Nat Commun"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-15-0730","article-title":"Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models","volume":"15","author":"Punnoose","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2015.02.006","article-title":"Sustained proliferation in cancer: Mechanisms and novel therapeutic targets","author":"Feitelson","year":"2015","journal-title":"Semin Cancer Biol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2026.101355","article-title":"The hallmarks of oncogenic signaling: From pathways to resistance in cancer therapy","volume":"85","author":"Tufail","year":"2026","journal-title":"Drug Resist Update"},{"key":"B28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40364-025-00745-7","article-title":"Focal adhesion in the tumour metastasis: from molecular mechanisms to therapeutic targets","volume":"13","author":"Liu","year":"2025","journal-title":"biomark Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.629266","article-title":"DNA repair pathways in cancer therapy and resistance","volume":"11","author":"Li","year":"2020","journal-title":"Front Pharmacol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01388","article-title":"Harnessing DNA double-strand break repair for cancer treatment","volume":"9","author":"Trenner","year":"2019","journal-title":"Front Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/1754-9485.13413","article-title":"Impact of DNA damage response defects in cancer cells on response to immunotherapy and radiotherapy","volume":"66","author":"Czajkowski","year":"2022","journal-title":"J Med Imaging Radiat Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2025.101287","article-title":"Targeting DNA damage response pathways in tumor drug resistance: Mechanisms, clinical implications, and future directions","volume":"83","author":"Zhu","year":"2025","journal-title":"Drug Resist Update"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.216043","article-title":"CD8(+) T cell exhaustion and cancer immunotherapy","volume":"559","author":"Wang","year":"2023","journal-title":"Cancer Lett"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70345","article-title":"Unravelling T cell exhaustion through co-inhibitory receptors and its transformative role in cancer immunotherapy","volume":"15","author":"Xiang","year":"2025","journal-title":"Clin Transl Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1146\/annurev-immunol-090222-110914","article-title":"T cell exhaustion","volume":"42","author":"Baessler","year":"2024","journal-title":"Annu Rev Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023019961","article-title":"Escape from T-cell-targeting immunotherapies in acute myeloid leukemia","volume":"143","author":"Vadakekolathu","year":"2024","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.3390\/cells10123376","article-title":"The role of T cell immunotherapy in acute myeloid leukemia","volume":"10","author":"Hao","year":"2021","journal-title":"Cells"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-020-00012-1","article-title":"Cancer metabolism and intervention therapy","volume":"2","author":"Zhao","year":"2021","journal-title":"Mol BioMed"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.2104oia169","article-title":"T cell metabolism drives immunity","volume":"212","author":"Buck","year":"2015","journal-title":"J Exp Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.cmet.2019.05.016","article-title":"Acylglycerol kinase maintains metabolic state and immune responses of CD8(+) T cells","volume":"30","author":"Hu","year":"2019","journal-title":"Cell Metab"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-025-01347-1","article-title":"Targeting MondoA-TXNIP restores antitumour immunity in lactic-acid-induced immunosuppressive microenvironment","volume":"7","author":"Xu","year":"2025","journal-title":"Nat Metab"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1918117\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:34:57Z","timestamp":1789533297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1918117\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":41,"alternative-id":["10.3389\/fonc.2026.1918117"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1918117","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"article-number":"1918117"}}